- Home
- WBS vs ABVX Comparison
WBS vs ABVX Comparison
Compare WBS & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | WBS | ABVX |
|---|---|---|
| Founded | 1935 | 2013 |
| Country | United States | France |
| Employees | 4601 | 67 |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 9.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WBS | ABVX |
|---|---|---|
| Price | $71.93 | $106.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 13 |
| Target Price | $73.64 | ★ $131.31 |
| AVG Volume (30 Days) | ★ 2.5M | 773.7K |
| Earning Date | 04-28-2026 | 03-23-2026 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.32 | $52.14 |
| Revenue Next Year | $5.89 | $4,132.27 |
| P/E Ratio | $12.28 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $46.81 | $5.59 |
| 52 Week High | $74.00 | $148.83 |
Technical Indicators
Market Signals| Indicator | WBS | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 55.76 | 38.54 |
| Support Level | $70.89 | $100.33 |
| Resistance Level | $73.92 | $108.00 |
| Average True Range (ATR) | 0.68 | 5.07 |
| MACD | -0.10 | -1.34 |
| Stochastic Oscillator | 24.71 | 0.67 |
Price Performance
Historical ComparisonAbout WBS Webster Financial Corporation
Webster Financial Corp is a full-service provider of financial services, offering commercial and consumer banking, mortgages, and investment advisory along with trust and wealth management services in Connecticut, New York, Rhode Island, Massachusetts, and Pennsylvania. The company's segment includes Commercial Banking, HSA Bank, and Consumer Banking. It generates maximum revenue from the Commercial Banking segment.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.